The complement factor H (FH) mutation R1210C, which was described in association with atypical Hemolytic Uremic Syndrome (aHUS), also confers high risk of Age-related Macular Degeneration (AMD) and is associated with C3-Glomerulopathy (C3G). To provide insight into what determines the disease phenotype in FH-R1210C carriers and to reveal the molecular basis of these associations, we searched and identified FH-R1210C carriers in our aHUS, C3G and AMD cohorts. Disease status, determined in patients and relatives, revealed absence of AMD phenotypes in the aHUS cohort and, vice versa, lack of renal disease in the AMD cohort. These findings were consistent with differences in the R1210C-independent overall risk for aHUS and AMD between mutation carriers developing one or the other pathology. R1210C is an unusual mutation that generates covalent complexes between FH and human serum albumin (HSA). Using purified FH proteins and surface plasmon resonance analyses we demonstrate that formation of these FH-HSA complexes impairs accessibility to all FH functional domains. These data show that R1210C is a unique C-terminal FH mutation that behaving as a partial FH deficiency predisposes to diverse pathologies with distinct underlying pathogenic mechanisms; the final disease outcome is then determined by R1210C-independent genetic risk factors.
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Complement is a key component of innate immunity that activates in the presence of pathogens, immune complexes or apoptotic cells. It is able to discriminate between self and foreign/altered-self components and, through a system of molecular labeling, to identify the latter for elimination by opsonophagocytosis or destruction by direct cell lysis. Complement, however, requires strict regulation to focus its action on the surface responsible for its activation and to avoid complete consumption after activation. Loss of complement regulation leads to the generation of pro-inflammatory components and/or damage to our own tissues, both of which have pathological consequences (1, 2) . Factor H (FH), the most important alternative pathway complement regulator, is an abundant plasma glycoprotein composed of 20 repetitive units (short consensus repeats, SCRs) that regulates complement in fluid phase and on cellular surfaces. The regulatory activities of the FH molecule depend on three major functional domains, an N-terminal domain (SCR1-4) that sustains the cofactor and decay accelerating activities and two domains in SCR6/7 and SCR19/20, which are relevant for ligand binding and cell surface recognition (3). As described, FH is a multifunctional protein and it should be expected that mutations that eliminate, completely or partially, all or some of these functional sites would cause specific FH dysfunctions with distinct pathological consequences.
aHUS, AMD and C3G are examples of diseases in which chronic inflammation and tissue damage play an important role and that have been associated with mutations and polymorphisms in different genes encoding complement proteins (4) (5) (6) . Despite sharing complement dysregulation, they are distinct pathologies with different underlying pathogenic mechanisms. These differences are reflected by strong genotype-phenotype correlations in different complement genes. Among these correlations, mutations that alter the C-terminal region of FH are prototypical of aHUS (7) (8) (9) , whereas the Y402H polymorphism in SCR7 of FH is a unique risk factor for AMD (10) (11) (12) (13) , and complete FH deficiency or homozygous mutations in the N-terminal region of FH associate with C3G (14, 15) . In this context, the association of the C-terminal FH-4 R1210C mutation with aHUS (16), AMD (17) (18) (19) and C3G (20) , challenges these genotype-phenotype correlations, suggesting previously unrecognized pathogenic links between these disorders. Here, we performed experiments to reveal the molecular basis of these associations and to identify what determines the disease outcome in FH-R1210C carriers.
Consistent with previous reports, we identified 25 R1210C carriers in our aHUS cohort (n=1030), 2 in the C3G cohort (n=187), 5 in the AMD cohort (n=259) and none in a control group (n=330). Among these carriers there are both, affected and healthy individuals (Figure 1a) , illustrating the incomplete penetrance of the three diseases among R1210C mutation carriers. We also observed that in the two R1210C AMD pedigrees that we have identified, similarly to earlier data (17) , some individuals developed AMD in the absence of the R1210C mutation (Figure 1b) . These data are in agreement with FH-R1210C being associated with aHUS, AMD and C3G. They also indicate that, at least, in our R1210C AMD pedigrees, there is an independent and strong genetic predisposition to AMD.
Notably, within a given pedigree, R1210C carriers only develop one type of disease.
Raychaudhuri and co-workers found no evidence of clinically significant renal dysfunction among 17 unrelated R1210C heterozygotes with advanced AMD (17) .
Likewise, we found that none of the 27 carriers of the R1210C mutation among our aHUS and C3G patients and their relatives, including 8 over 55y-old, reported AMDlike visual impairment or presented signs of AMD in fundus examination using standardizated protocols (Figure 1a) . We have reported earlier that the presence of additional aHUS genetic risk factors significantly contributes to the manifestation of aHUS among R1210C carriers (16) . Therefore, we hypothesized that differences in the R1210C-independent overall genetic risk for AMD and aHUS influence the penetrance of one or other disease among these individuals.
The AMD risk genotypes for previously published AMD cases carrying R1210C
have not been reported and we only found two affected R1210C carriers in our AMD 5 cohort. Although this is a very small number, these two AMD cases belong to pedigrees with multiple affected individuals (Figure 1b) , suggesting, as indicated above, an elevated overall AMD risk in these families that is independent of the R1210C mutation. In fact, the average overall AMD genetic risk (See Methods) for all members in these families (n= 22) is 60.6 ( Figure 2 and Supplementary Figure 1) , raising to 74 for affected members only (n=8), which are very high AMD risks considering that the average AMD risk for the whole Spanish AMD cohort (n=259) is 67.3 ( Figure 2 and Table 1 ). In contrast, the overall AMD risks among the aHUS (n=13; 44.8) and healthy (n=16; 49.9) R1210C carriers are similar to the control Spanish group (n=191; 44.3) ( Figure 2 and Table 1 ). Correspondingly, aHUS risk scores (See Methods) in the 13 aHUS patients were significantly elevated compared to those in the 16 healthy R1210C mutation carriers (2.46 vs 0.88, p<0.001) and, consistently, aHUS risk scores were significantly decreased among members of the two AMD pedigrees (n=22) compared with the 13 aHUS patients (0.38 vs 2.46; p<0.001) ( Figure 2 and Table 1 ). As a whole, these data indicate that additional genetic risk factors independent of the FH-R1210C mutation contribute significantly to the disease outcome in R1210C carriers in our cohorts.
The association of the R1210C mutation with AMD and C3G challenges the strong genotype-phenotype correlation that characterizes the FH C-terminal mutations.
FH C-terminal mutations are prototypical of aHUS and the most prevalent genetic alteration among these patients (7, 21, 22) . It is now well established that the FH Cterminal region binds simultaneously C3b (or C3dg) and polyanions, like glycosaminoglycans, sulphated polysaccharides or sialylated glycans, on the host cell surfaces through separate domains in SCR19 and SCR20 (23). Compelling evidence has shown that C-terminal mutations in FH associated with aHUS impair the capacity of FH to protect host endothelial cells from complement lysis (21, 22) . Similarly, the FH-Y402H polymorphism in SCR7 is characteristically associated with AMD (9-12). The mechanism by which the FH-Y402H polymorphism impacts AMD risk is as yet unsolved, although it is thought that it alters the ligand specificity of the FH SCR6/7 domain, which may result in failure to recruit FH to sites where complement is activated by the accumulation of endogenous complement-activating compounds in the retina. In this respect, it has been reported that the AMD risk FH-402H variant fails to bind a number of ligands, including CRP, heparan sulfate and malondialdehyde, a common lipid peroxidation product found in the aged retina and implicated in AMD (24-26).
Integrity of the surface recognition domains in SCR6/7 and SCR19/20 are, therefore, distinctively critical in the pathogenesis of AMD and aHUS, respectively. Then, why does the C-terminal FH-R1210C mutation predispose to AMD and C3G?
Crucially, from a structural point of view the R1210C mutation is very different from other FH C-terminal mutations in that this mutant forms covalently-linked complexes with HSA via the mutant cysteine residue (22). An explanation for the association of FH-R1210C with aHUS, AMD and C3G is that the HSA molecule linked to the Cterminal region of FH not only interferes the interaction of this region with its ligands, impairing the C-terminus functionalities, but also disturbs the interaction of the SCR6/7 and the N-terminal regions with their ligands on the complement activating surface.
Testing this possibility is complex because we lack ligands uniquely recognized by each of these FH functional domains. To overcome these difficulties we selected three monoclonal antibodies (moAbs) that specifically impair the function of each of these FH regions, the N-terminal moAb OX24, the anti FH-402Tyr moAb MBI-6 (or anti FH402His MBI-7) and the C-terminal moAb A229, respectively. Using FH purified proteins (Supplementary Figure 2) and surface plasmon resonance (SPR) analysis we were able to show that the binding affinities of the three moAbs for FH-R1210C were significantly decreased compared to those for FH-WT (Figure 3a) . Importantly, these differences in all cases resulted from a decreased association constant (K on ),
demonstrating that accessibility to all three FH functional regions was impaired in the FH-R1210C mutant ( Figure 3a) . As an additional control we included in these analyses a FH mutant protein carrying two missense mutations (S1129L, V1191I) in the SCR20 of FH and that exclusively associates with aHUS. This additional mutant illustrates that it is the albumin bound to FH and not the C-terminal mutation that impairs accessibility to the FH functional domains in the R1210C mutant (Supplementary Figure 3) .
Fifteen years ago we were unable to document differences between FH-WT and FH-R1210C in the N-terminal-dependent functional activities (22). However, consistent with the new data reported here, a reevaluation of these FH activities using SPR demonstrated that the AP C3 convertase decay accelerating activity of FH-R1210C, which is dependent of the FH N-terminal region, is impaired in the FH-R1210C mutant, but not in the aHUS-specific C-terminal FH-S1129L, V1191I mutant ( Figure 3b) .
As a whole, these data explain that carriers of the FH-R1210C mutation develop aHUS, AMD or C3G not because these disorders share unrecognized pathogenic links, but because this FH mutant is an exception to the strict genotype-phenotype correlations that characterize these diseases. Impairing all FH functionalities, the consequences of the FH-R1210C mutation are equivalent to a partial FH deficiency, which is well documented to be associated with a broad spectrum of pathologies with distinct underlying pathogenic mechanisms. In carriers of partial FH deficiencies, like in FH-R1210C carriers, the final outcome is determined by the individual's overall genetic risk to each of these diseases. Thus, available evidence suggest that concurrence of a partial FH deficiency with other mutations/polymorphisms decreasing protection to host cells will result in aHUS, whereas the coincidence of partial FH deficiencies with strong fluid-phase complement activators, galactose-deficient IgA1-containing immune complexes or AMD-risk polymorphism will trigger C3G, IgAN or AMD (14,37-30), respectively. Additional genetic and/or environmental factors altering host surfaces, depositing activating molecules (i.e, CRP, malondialdehyde) or removing FH ligands (i.e., heparan sulfate, sialic acid), might also influence the pathological outcome in these individuals. Our report further illustrates the relevance of understanding the functional consequences of the disease-associated mutations to provide insight into pathogenic mechanisms.
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Concise Methods
Further information is available in Supplemental Methods
Overall genetic risks for aHUS and AMD and statistical analyses. To evaluate the AMD risk scores we used a model developed in our laboratory that includes the most relevant polymorphisms associated with AMD (31) . Briefly, this model considers the genotypes at the triallelic locus CFHR1 in addition to the genotypes of the CFH Tyr402His, CFB Leu9His, CFB Arg32Gln/Trp and ARMS2 Ala69Ser polymorphisms.
Regression coefficients (risk scores) were determined for all the genotypes using multivariate logistic regression analysis as previously described (31) . Cumulative risk scores (Z) were determined by the equation Z=α+Σβ i X i where the regression coefficients α (constant) and β i (risk score specific for each genotype X) are taken directly form the multivariate logistic regression analysis. In this work we are using probabilities of developing AMD (P). P values were calculated as P=e Z /(1+e Z ). As an example, for a population like Spain with a prevalence of AMD (grades 2, 3 and 4) of 16% over 65 years of age, 19 % of individuals with a P value of 60% will present AMD, whereas this percentage decreases to 9.3 % for those with a P value of 40% (31).
Because we have no similar models for the calculation of the overall risk for aHUS, we have considered in this estimation the presence of mutations in additional aHUS candidate genes and the genotypes for the CFH-H3 and MCPggaac aHUS risk haplotypes (32) . We therefore gave one point for each additional mutation or risk polymorphism, and the sum of the codes was used as a continuous variable. In contrast to the overall AMD risk (P values), ranging from 0% to 100%, the overall risk for aHUS are increasing numerals. That is: 0, 1, 2, 3, etc. One-way analysis of variance with Tukey's post hoc test was used to test differences between the groups. All tests were performed using SPSS version 21 statistical software (SPSS Inc., Chicago, IL, USA). A p-value <0.05 was considered statistically significant. Our study also includes two R1210C pedigrees including 8 cases with AMD (2 carrying R1210C) and 3 healthy R1210C carriers. These pedigrees also include 11 healthy relatives who did not carry the R1210C mutation. AMD patients were recruited by the Department of Ophthalmology, Clínica Universidad de Navarra, Pamplona, Spain.
AMD was diagnosed by the presence of drusen and a chorioretinal macular atrophy involving central macula or signs related to CNV in at least one eye.
Genotyping and mutation screening. Genomic DNA was extracted from peripheral blood using standard procedures or from oral swabs using QIAcube (QIAGEN, CFB and THBD genes were amplified from genomic DNA using primers derived from the intronic sequences as described (4) (5) (6) (7) (8) (9) . Automatic sequencing was performed in an ABI3730 sequencer using a dye terminator cycle sequencing kit (Applied Biosystems).
The analysis of the Δ CFHR3-CFHR1 polymorphism and genomic rearrangements in the CFH-CFHRs region was by multiplex ligation-dependent probe amplification (MLPA) with the P236 A1 ARMD mix 1 (MRC-Holland, Amsterdam, Netherlands).
Purification of WT and mutant FHs. FH-WT, FH-R1210C and FH-S1129L-V1191I were purified to homogeneity from plasma of appropriate donors by affinity chromatography.
Three affinity chromatography columns were used following the scheme depicted in Suppl. Fig. 4 . Thirty mg of 214 moAb (anti-human FH, in-house) was coupled to a 5ml
CNBr-activated Sepharose 4B column according to the manufacturer's instructions (GE Healthcare). Similarly, thirty mg of FH-402His moAb MBI-7 (anti-human FH-402His variant, in-house) was coupled to a 5ml CNBr-activated Sepharose 4B column. HiTrap
Albumin and IgG depletion columns (GE Healthcare) were used to separate WT and 4 samples were then flowed at 70 nM during 500s at a flow rate of 10 µl/min and decay accelerating activity was monitored. Spontaneous decay was monitored by flowing running buffer instead of FH. The C3b surface was regenerated with 100mM sodium acetate pH 4.0, NaCl 500 mM. Three independent decay experiments with identical results were performed for each FH variant. All signals were double-referenced (data from a reference cell and blank injection subtracted).
